Quantcast
Last updated on April 23, 2014 at 11:18 EDT

Latest Oncology Stories

2014-03-26 16:11:46

A breast cancer therapy that blocks estrogen synthesis to activate cancer-killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (UPCI). The finding warrants research into adding drugs that could prevent the cancer from hijacking patients' repressive gene...

2014-03-26 12:26:20

The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., March 26, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 45 percent of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or metastatic melanoma compared with 28...

2014-03-26 08:24:59

SAN DIEGO, March 26, 2014 /PRNewswire/ -- Latest special issue of journal Gynecologic Oncology addresses the impact of obesity on gynecologic cancer patients, oncologists and cancer care delivery systems The journal Gynecologic Oncology, the official journal of the Society of Gynecologic Oncology, is pleased to announce the launch of a special issue [http://www.sciencedirect.com/science/journal/00908258/133 ] on gynecologic cancer prevention, treatment and...

2014-03-26 08:23:02

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pt8tl4/treating ) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer through innovative drug development strategies have...

2014-03-26 04:20:54

First System to Prevent Syringe Plunger Contamination Demonstrated at Barcelona, New Orleans, and Montreal Conferences BARCELONA, Spain, March 26, 2014 /PRNewswire/ -- Equashield (http://www.equashield.com [http://../ari/AppData/Local/Microsoft/Windows/Temporary InternetFiles/Content.Outlook/ZS150YTY/www.equashield.com ] ), the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced its participation in three upcoming...

2014-03-25 23:28:12

GIA announces the release of a comprehensive global report on Circulating Tumor Cells and Cancer Stem Cells Technologies markets. Global market for Circulating Tumor Cells (CTC) Diagnostics is forecast to reach US$10 billion by 2020, driven by rising incidence of cancer, growing demand for effective diagnosis & treatment, and breakthrough research developments in understanding disease pathways. San Jose, California (PRWEB) March 25, 2014 Follow us on LinkedIn – High prevalence of...

2014-03-25 08:29:51

Inspired to save the lives of Coachella Valley cancer patients, BIGHORN Behind a Miracle (BAM) reached an exciting milestone of raising $1 million at their kick-off party, A Night of Miracles, for BIGHORN BAM Week that also includes a Caddy Auction and Golf Tournament. PALM DESERT, Calif., March 25, 2014 /PRNewswire/ -- BIGHORN BAM Founder Selby Dunham took her breast cancer survivor story and decided to give back to the hospital and community she loves so much. In the past 7...

2014-03-25 08:27:28

- Livenation.com and Ticketmaster.com Give Fans Opportunity to Help Fight Cancer through April 13, 2014 - LOS ANGELES, March 25, 2014 /PRNewswire/ -- Live Nation Entertainment (NYSE: LYV) and the American Cancer Society announced today a collaboration to raise awareness of cancer issues and critically needed funds to help finish the fight. http://photos.prnewswire.com/prnvar/20140325/LA85683LOGO Fans of concerts, sports, theater and family events can make a donation to help fight...

2014-03-24 23:27:51

Lead Candidate Provides Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) March 24, 2014 ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancer announced today that P2045, the Company's lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC). Orphan...

2014-03-24 23:24:12

Japanese researchers say the drug Alimta (pemetrexed) in combination with cisplatin should remain the top first-line treatment for malignant pleural mesothelioma. Raleigh, NC (PRWEB) March 24, 2014 Japanese researchers say the drug Alimta (pemetrexed) in combination with cisplatin should remain the top first-line treatment for malignant pleural mesothelioma. Their findings have just been posted by Surviving Mesothelioma at...